UGGT2: A Potential Drug Target Or Biomarker for Disease (G55757)

Target Name: UGGT2

NCBI ID: G55757

UGGT2

UGGT2: A Potential Drug Target Or Biomarker for Disease

UGGT2 (MGC87276) is a gene that encodes for a protein known as UGGT2, which is a type of gamma-secretase enzyme that is involved in the processing of DNA in the cell. UGGT2 is a crucial enzyme that helps to maintain the integrity of DNA and has been implicated in a number of cellular processes, including DNA repair, apoptosis, and inflammation.

Recent studies have suggested that UGGT2 may be a drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because UGGT2 has been shown to be overexpressed or mutated in a variety of cancer types, including breast, ovarian, and colorectal cancer. Additionally, UGGT2 has been linked to a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, and has been shown to be involved in the development of neurofibrillary tangles and neurodegeneration in these conditions.

One of the potential benefits of targeting UGGT2 is that it has been shown to be involved in a number of cellular processes that are important for the development and progression of disease. For example, UGGT2 has been shown to play a role in the regulation of cell death, and has been linked to the production of pro-inflammatory cytokines that can contribute to the development of neurodegeneration. Additionally, UGGT2 has been shown to be involved in the regulation of DNA replication and repair, which is important for the maintenance of cellular genome stability and has been implicated in a number of diseases, including cancer.

Another potential benefit of targeting UGGT2 is that it has been shown to be a potential therapeutic target for a number of diseases. For example, studies have shown that UGGT2 may be a potential therapeutic target for breast cancer, as UGGT2 overexpression has been shown to contribute to the development and progression of breast cancer. Additionally, UGGT2 has been shown to be involved in the development of neurofibrillary tangles and neurodegeneration in conditions such as Alzheimer's and Parkinson's diseases, and targeting UGGT2 may be a potential way to treat these conditions.

In conclusion, UGGT2 is a gene that encodes for a protein that is involved in a number of cellular processes that are important for the development and progression of disease. Recent studies have suggested that UGGT2 may be a drug target or biomarker for a number of diseases, including cancer and neurodegenerative conditions. Further research is needed to fully understand the role of UGGT2 in disease and to develop effective therapies that target this protein.

Protein Name: UDP-glucose Glycoprotein Glucosyltransferase 2

Functions: Recognizes glycoproteins with minor folding defects. Reglucosylates single N-glycans near the misfolded part of the protein, thus providing quality control for protein folding in the endoplasmic reticulum. Reglucosylated proteins are recognized by calreticulin for recycling to the endoplasmic reticulum and refolding or degradation

The "UGGT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGGT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets